Eficacia del anticuerpo Glofitamab como tratamiento de linfoma no Hodgkin. Revisión sistemática

Abstract

Introduction: Non-Hodgkin Lymphoma (NHL) is a hematological malignancy originating in B or T lymphocytes or natural killer cells. Current studies have evaluated therapy with glofitamab one of the most innovative bispecific monoclonal antibodies in the field of oncology. General objective: To determine the efficacy of the antibody glofitamab as a treatment for NHL. Methodology: A descriptive, systematic review was conducted. Articles from high-impact journals published within the last five years were retrieved from the following databases: PubMed, Scopus, and ProQuest. Search terms were based on DeCS and MeSH. Article selection followed the PRISMA guidelines. Results: Clinical trials demonstrated efficacy results for glofitamab, with an overall response rate of approximately 52% and a progression-free survival rate of 12 to 24 months. In refractory or regressing patients from prior therapies, glofitamab demonstrated favorable activity, with a durable complete response and a predictable, manageable safety profile. However, cytokine release syndrome was identified as the primary adverse effect.